Challenges of Integrative Disease Modeling in Alzheimer's Disease
暂无分享,去创建一个
Martin Hofmann-Apitius | Charles Tapley Hoyt | Daniel Domingo-Fernández | Christine Robinson | Sepehr Golriz Khatami | Colin Birkenbihl | M. Hofmann-Apitius | C. Birkenbihl | C. Robinson | D. Domingo-Fernándéz | Sepehr Golriz Khatami
[1] Henrik Zetterberg,et al. Determining cut-points for Alzheimer's disease biomarkers: statistical issues, methods and challenges. , 2012, Biomarkers in medicine.
[2] Anil Rao,et al. Classification of Alzheimer's Disease from structural MRI using sparse logistic regression with optional spatial regularization , 2011, 2011 Annual International Conference of the IEEE Engineering in Medicine and Biology Society.
[3] Sébastien Ourselin,et al. Multiple Orderings of Events in Disease Progression , 2015, IPMI.
[4] Raul Rodriguez-Esteban,et al. Biocuration with insufficient resources and fixed timelines , 2015, Database J. Biol. Databases Curation.
[5] Diego Castillo-Barnes,et al. Studying the Manifold Structure of Alzheimer's Disease: A Deep Learning Approach Using Convolutional Autoencoders , 2020, IEEE Journal of Biomedical and Health Informatics.
[6] C. Jack,et al. Alzheimer's Disease Neuroimaging Initiative , 2008 .
[7] Arthur W. Toga,et al. Practical management of heterogeneous neuroimaging metadata by global neuroimaging data repositories , 2012, Front. Neuroinform..
[8] T. Tombaugh. Test-retest reliable coefficients and 5-year change scores for the MMSE and 3MS. , 2005, Archives of clinical neuropsychology : the official journal of the National Academy of Neuropsychologists.
[9] Ernesto Fedele,et al. The Amyloid Cascade Hypothesis in Alzheimer’s Disease: It’s Time to Change Our Mind , 2017, Current neuropharmacology.
[10] Ronald C Petersen,et al. New criteria for Alzheimer's disease: which, when and why? , 2015, Brain : a journal of neurology.
[11] Jonathan R. Walsh,et al. Machine learning for comprehensive forecasting of Alzheimer’s Disease progression , 2018, Scientific Reports.
[12] Sebastien Ourselin,et al. Uncovering the heterogeneity and temporal complexity of neurodegenerative diseases with Subtype and Stage Inference , 2017, bioRxiv.
[13] M W Weiner,et al. The relative efficiency of time-to-threshold and rate of change in longitudinal data. , 2011, Contemporary clinical trials.
[14] Daoqiang Zhang,et al. Tree-Guided Sparse Coding for Brain Disease Classification , 2012, MICCAI.
[15] Mingshan Wang,et al. Publication Trends for Alzheimer's Disease Worldwide and in China: A 30-Year Bibliometric Analysis , 2019, Front. Hum. Neurosci..
[16] Eric E. Smith,et al. Determining the impact of psychosis on rates of false-positive and false-negative diagnosis in Alzheimer's disease , 2017, Alzheimer's & Dementia.
[17] Mladen Konecki,et al. Mind map generator software model with text mining algorithm , 2011, Proceedings of the ITI 2011, 33rd International Conference on Information Technology Interfaces.
[18] G. B. Frisoni,et al. The dynamics of Alzheimer's disease biomarkers in the Alzheimer's Disease Neuroimaging Initiative cohort , 2010, Neurobiology of Aging.
[19] Francisco M. Couto,et al. Text Mining for Bioinformatics Using Biomedical Literature , 2019, Encyclopedia of Bioinformatics and Computational Biology.
[20] Gokul Prabhakaran,et al. Analysis of Structure and Cost in an American Longitudinal Study of Alzheimer's Disease , 2018 .
[21] Alind Gupta,et al. Bayesian Networks for Risk Prediction Using Real-World Data: A Tool for Precision Medicine. , 2019, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[22] David Gomez-Cabrero,et al. Data integration in the era of omics: current and future challenges , 2014, BMC Systems Biology.
[23] Neil P. Oxtoby,et al. Imaging plus X: multimodal models of neurodegenerative disease , 2017, Current opinion in neurology.
[24] Jing Ning,et al. Non‐parametric tests for right‐censored data with biased sampling , 2010, Journal of the Royal Statistical Society. Series B, Statistical methodology.
[25] D. Delis,et al. Quantification of five neuropsychological approaches to defining mild cognitive impairment. , 2009, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.
[26] Pamela C. Heaton,et al. Impact of the Food and Drug Administration’s antipsychotic black box warning on psychotropic drug prescribing in elderly patients with dementia in outpatient and office-based settings , 2012, Alzheimer's & Dementia.
[27] Henrik Zetterberg,et al. Effect of ponezumab on CSF biomarkers: Pooled analysis of phase IIa studies in subjects with mild-to-moderate Alzheimer's disease , 2012, Alzheimer's & Dementia.
[28] Daniela Stan Raicu,et al. Automatic extraction of informal topics from online suicidal ideation , 2018, BMC Bioinformatics.
[29] Martin Hofmann-Apitius,et al. Towards a Pathway Inventory of the Human Brain for Modeling Disease Mechanisms Underlying Neurodegeneration. , 2016, Journal of Alzheimer's disease : JAD.
[30] J. Trojanowski,et al. Integration and relative value of biomarkers for prediction of MCI to AD progression: Spatial patterns of brain atrophy, cognitive scores, APOE genotype and CSF biomarkers , 2013, NeuroImage: Clinical.
[31] Sébastien Ourselin,et al. An event-based model for disease progression and its application in familial Alzheimer's disease and Huntington's disease , 2012, NeuroImage.
[32] Howard Aizenstein,et al. Why we need two cutoffs for amyloid imaging: Early versus Alzheimer's-like amyloid-positivity , 2012, Alzheimer's & Dementia.
[33] Benjamin M. Gyori,et al. From word models to executable models of signaling networks using automated assembly , 2017, bioRxiv.
[34] Nicholas Ostler,et al. Corpus Design Criteria , 1992 .
[35] M. Jorge Cardoso,et al. Accurate multimodal probabilistic prediction of conversion to Alzheimer's disease in patients with mild cognitive impairment☆ , 2013, NeuroImage: Clinical.
[36] Roy W Jones,et al. On the path to 2025: understanding the Alzheimer’s disease continuum , 2017, Alzheimer's Research & Therapy.
[37] Wenrui Hao,et al. Computational Causal Modeling of the Dynamic Biomarker Cascade in Alzheimer's Disease , 2019, Comput. Math. Methods Medicine.
[38] Martin Hofmann-Apitius,et al. A Computational Approach for Mapping Heme Biology in the Context of Hemolytic Disorders , 2019, bioRxiv.
[39] Meemansa Sood,et al. Variational Autoencoder Modular Bayesian Networks (VAMBN) for Simulation of Heterogeneous Clinical Study Data , 2019, bioRxiv.
[40] A. Fagan,et al. Guidelines for the standardization of preanalytic variables for blood-based biomarker studies in Alzheimer's disease research , 2015, Alzheimer's & Dementia.
[41] Vikas Singh,et al. MKL for Robust Multi-modality AD Classification , 2009, MICCAI.
[42] Nick C Fox,et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. , 2012, The New England journal of medicine.
[43] T. Gale,et al. Sex differences in cognitive impairment in Alzheimer's disease. , 2016, World journal of psychiatry.
[44] Matthew L Senjem,et al. Shapes of the trajectories of 5 major biomarkers of Alzheimer disease. , 2012, Archives of neurology.
[45] Cynthia Rudin,et al. Stop explaining black box machine learning models for high stakes decisions and use interpretable models instead , 2018, Nature Machine Intelligence.
[46] H. Hu Victor,et al. Demographic and clinical characteristics. , 2016 .
[47] Denise C. Park,et al. Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.
[48] A. Baghestani,et al. How to control confounding effects by statistical analysis , 2012, Gastroenterology and hepatology from bed to bench.
[49] Anne M. Fagan,et al. CSF Biomarkers of Alzheimer’s Disease: Impact on Disease Concept, Diagnosis, and Clinical Trial Design , 2014 .
[50] C. Jack,et al. Evidence for ordering of Alzheimer disease biomarkers. , 2011, Archives of neurology.
[51] KongFatt Wong-Lin,et al. A hybrid computational approach for efficient Alzheimer’s disease classification based on heterogeneous data , 2018, Scientific Reports.
[52] Amy P. Abernethy,et al. Harnessing the Power of Real‐World Evidence (RWE): A Checklist to Ensure Regulatory‐Grade Data Quality , 2017, Clinical pharmacology and therapeutics.
[53] H. Benali,et al. Support vector machine-based classification of Alzheimer’s disease from whole-brain anatomical MRI , 2009, Neuroradiology.
[54] Tim Schultz,et al. Disease progression model in subjects with mild cognitive impairment from the Alzheimer's disease neuroimaging initiative: CSF biomarkers predict population subtypes. , 2013, British journal of clinical pharmacology.
[55] Christoforos Hadjichrysanthou,et al. A Systematic Review of Longitudinal Studies Which Measure Alzheimer’s Disease Biomarkers , 2017, Journal of Alzheimer's disease : JAD.
[56] M. Hofmann-Apitius,et al. From integrative disease modeling to predictive, preventive, personalized and participatory (P4) medicine , 2013, EPMA Journal.
[57] Magda Tsolaki,et al. The interactive effect of demographic and clinical factors on hippocampal volume: A multicohort study on 1958 cognitively normal individuals , 2017, Hippocampus.
[58] Jonathan A C Sterne,et al. Accounting for missing data in statistical analyses: multiple imputation is not always the answer , 2019, International journal of epidemiology.
[59] Mark Singh,et al. Prioritization of Free-Text Clinical Documents: A Novel Use of a Bayesian Classifier , 2015, JMIR medical informatics.
[60] C. Jack,et al. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers , 2013, The Lancet Neurology.
[61] Ainhoa Berciano-Alcaraz,et al. A computational approach of , 2010 .
[62] Daniel C Alexander,et al. Data-driven models of dominantly-inherited Alzheimer’s disease progression , 2018, bioRxiv.
[63] Jon Neville,et al. Accelerating drug development for Alzheimer's disease through the use of data standards , 2017, Alzheimer's & dementia.
[64] R. Kolamunnage-Dona,et al. Time-dependent ROC curve analysis in medical research: current methods and applications , 2017, BMC Medical Research Methodology.
[65] S. Resnick,et al. Midlife adiposity predicts earlier onset of Alzheimer’s dementia, neuropathology and presymptomatic cerebral amyloid accumulation , 2015, Molecular Psychiatry.
[66] Nick C. Fox,et al. Data-driven models of dominantly-inherited Alzheimer’s disease progression , 2018 .
[67] Julia Moeller,et al. A word on standardization in longitudinal studies: don't , 2015, Front. Psychol..
[68] Danilo Bzdok,et al. Classical Statistics and Statistical Learning in Imaging Neuroscience , 2016, Front. Neurosci..
[69] Demetrius J Porche,et al. Precision Medicine Initiative , 2015, American journal of men's health.
[70] Timothy J. Hohman,et al. Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimer’s disease risk , 2019, Nature Genetics.
[71] Bernhard Hemmer,et al. Consensus guidelines for lumbar puncture in patients with neurological diseases , 2017, Alzheimer's & dementia.
[72] Clifford R Jack,et al. Testing the Right Target and Right Drug at the Right Stage , 2011, Science Translational Medicine.
[73] Isabelle Boutron,et al. Misrepresentation and distortion of research in biomedical literature , 2018, Proceedings of the National Academy of Sciences.
[74] Michel Thiebaut de Schotten,et al. Biomarker-guided clustering of Alzheimer's disease clinical syndromes , 2019, Neurobiology of Aging.
[75] David T. Jones,et al. Defining imaging biomarker cut points for brain aging and Alzheimer's disease , 2017, Alzheimer's & Dementia.
[76] Genetic,et al. Genetic meta-analysis of diagnosed Alzheimer’s disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing , 2019, Nature Genetics.
[77] Randall J Bateman,et al. Dominantly Inherited Alzheimer Network: facilitating research and clinical trials , 2013, Alzheimer's Research & Therapy.
[78] K. Blennow,et al. Biomarkers for Alzheimer's disease: current status and prospects for the future , 2018, Journal of internal medicine.
[79] Nathan Herrmann,et al. Clinical practice guidelines for severe Alzheimer’s disease , 2007, Alzheimer's & Dementia.
[80] D. Louis Collins,et al. Early Prediction of Alzheimer's Disease Progression Using Variational Autoencoders , 2019, MICCAI.
[81] C. Rowe,et al. The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer's disease , 2009, International Psychogeriatrics.
[82] José Luis Molinuevo,et al. European Prevention of Alzheimer’s Dementia Longitudinal Cohort Study (EPAD LCS): study protocol , 2018, BMJ Open.
[83] Johann de Jong,et al. Deep learning for clustering of multivariate clinical patient trajectories with missing values , 2019, GigaScience.
[84] Christian Simon,et al. BioReader: a text mining tool for performing classification of biomedical literature , 2019, BMC Bioinformatics.
[85] Meng Wang,et al. Demographic and clinical characteristics related to cognitive decline in Alzheimer disease in China , 2016, Medicine.
[86] Eric Westman,et al. The heterogeneity within Alzheimer's disease , 2018, Aging.
[87] Nataša Pržulj,et al. Methods for biological data integration: perspectives and challenges , 2015, Journal of The Royal Society Interface.
[88] Christoph Bock,et al. Knowledge-primed neural networks enable biologically interpretable deep learning on single-cell sequencing data , 2019, Genome Biology.
[89] Christiane Reitz,et al. Toward precision medicine in Alzheimer's disease. , 2016, Annals of translational medicine.
[90] Bruno Vellas,et al. Predictive Factors of Attrition in a Cohort of Alzheimer Disease Patients , 2008, Neuroepidemiology.
[91] Holger Fröhlich,et al. From hype to reality: data science enabling personalized medicine , 2018, BMC Medicine.
[92] V. P. Gladun. Hypothetical modeling: Methodology and application , 1997 .
[93] B. Dubois,et al. A Precision Medicine Initiative for Alzheimer’s disease: the road ahead to biomarker-guided integrative disease modeling , 2017, Climacteric : the journal of the International Menopause Society.
[94] Michal Daszykowski,et al. Revised DBSCAN algorithm to cluster data with dense adjacent clusters , 2013 .
[95] Keith A. Johnson,et al. A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers , 2016, Neurology.
[96] Clare E. Mackay,et al. DEEP AND FREQUENT PHENOTYPING: A FEASIBILITY STUDY FOR EXPERIMENTAL MEDICINE IN DEMENTIA , 2017, Alzheimer's & Dementia.
[97] Robert Tibshirani,et al. Estimating the number of clusters in a data set via the gap statistic , 2000 .
[98] Giovanni B. Frisoni,et al. European Prevention of Alzheimer's Dementia Registry: Recruitment and prescreening approach for a longitudinal cohort and prevention trials , 2018, Alzheimer's & Dementia.
[99] Daoqiang Zhang,et al. Multimodal classification of Alzheimer's disease and mild cognitive impairment , 2011, NeuroImage.
[100] C. Jack,et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade , 2010, The Lancet Neurology.
[101] Nick C Fox,et al. Uncovering the heterogeneity and temporal complexity of neurodegenerative diseases with Subtype and Stage Inference , 2017, Nature Communications.
[102] Carole A. Goble,et al. State of the nation in data integration for bioinformatics , 2008, J. Biomed. Informatics.
[103] Martin Hofmann-Apitius,et al. Neuroimaging Feature Terminology: A Controlled Terminology for the Annotation of Brain Imaging Features , 2017, Journal of Alzheimer's disease : JAD.
[104] Dragan Gamberger,et al. Identification of clusters of rapid and slow decliners among subjects at risk for Alzheimer’s disease , 2017, Scientific Reports.
[105] P. Austin. An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies , 2011, Multivariate behavioral research.
[106] Vikas Singh,et al. Predictive markers for AD in a multi-modality framework: An analysis of MCI progression in the ADNI population , 2011, NeuroImage.
[107] Gang Chen,et al. Staging Alzheimer’s Disease Risk by Sequencing Brain Function and Structure, Cerebrospinal Fluid, and Cognition Biomarkers , 2016, Journal of Alzheimer's disease : JAD.
[108] Sylvain Paile,et al. WHAT TO CONTROL , 2013 .
[109] Paul M. Thompson,et al. Multi-source learning with block-wise missing data for Alzheimer's disease prediction , 2013, KDD.
[110] Charles DeCarli,et al. Biological heterogeneity in ADNI amnestic mild cognitive impairment , 2014, Alzheimer's & Dementia.
[111] Ryan M. Cassidy,et al. Risk factors for amyloid positivity in older people reporting significant memory concern. , 2018, Comprehensive psychiatry.
[112] Marilyn Albert,et al. Variation in Variables that Predict Progression from MCI to AD Dementia over Duration of Follow-up. , 2013, American journal of Alzheimer's disease.
[113] Nick C Fox,et al. The clinical use of structural MRI in Alzheimer disease , 2010, Nature Reviews Neurology.
[114] Pedro M. Domingos. A few useful things to know about machine learning , 2012, Commun. ACM.
[115] Mohammad Asif Emon,et al. Using Multi-Scale Genetic, Neuroimaging and Clinical Data for Predicting Alzheimer’s Disease and Reconstruction of Relevant Biological Mechanisms , 2018, Scientific Reports.